Skip to main content
The Globe and Mail
Get full access to globeandmail.com
Support quality journalism
Just $1.99 per week for the first 24weeks
Just $1.99 per week for the first 24weeks
The Globe and Mail
Support quality journalism
Get full access to globeandmail.com
Globe and Mail website displayed on various devices
Just$1.99
per week
for the first 24weeks

var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){console.log("scroll");var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))}pencilInit(".js-sub-pencil",!1);

Purdue Pharma filed for bankruptcy in September in the face of thousands of lawsuits alleging it helped fuel the opioid crisis

The Associated Press

OxyContin maker Purdue Pharma LP got court approval on Tuesday to reimburse millions of dollars in legal fees for states that back its proposed $10 billion settlement of opioid lawsuits, but with a condition meant to help victims of the addiction crisis.

Purdue had told Bankruptcy Judge Robert Drain at Tuesday’s hearing in White Plains, New York that paying the fees for seven firms that work on behalf of states and local governments would help bring structure to its Chapter 11 case and resolve it quickly.

Drain said he wanted reimbursement of the fees for four law firms, a financial adviser and two economic consultants conditioned on the parties reaching a deal on the quick release of emergency funds for victims.

Story continues below advertisement

Purdue proposed a $200 million emergency fund last month that could be spent quickly on addiction treatment while the parties resolve the entire bankruptcy case, a process that will take many months. Purdue has said the money has been tied up by disagreements among states, local governments and others parties over how to spend the funds.

Scott Markowitz, who represents guardians of children born with neonatal abstinence syndrome caused by opioid exposure in the womb, urged Drain to reject the reimbursement request.

“It’s difficult for me to explain to my constituents why states and government authorities which have the funds to pay lawyers get their fees paid when it could be used for a hospital,” he said. “We think it sends the wrong message to victims of the opioid crisis.”

Purdue filed for bankruptcy in September in the face of thousands of lawsuits alleging it helped fuel the opioid crisis by playing down the addiction risks of its painkillers, which Purdue has denied.

The company entered bankruptcy with a framework settlement it has said is worth $10 billion, supported by about two dozen states and the local governments that filed the bulk of the lawsuits.

As governments perform due diligence on the settlement, Purdue will reimburse their reasonable fees, which could reach $20 million, a lawyer for the official committee of unsecured creditors said at Tuesday’s hearing.

Purdue still faces significant opposition led by the attorneys general from New York and Massachusetts, who have said they want the Sackler family that owns Purdue to contribute more than the proposed $3 billion.

Story continues below advertisement

The Sacklers also have agreed to cede control of Purdue to those who are suing it, and sell overseas businesses.

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies